Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant

Verbost, P.M.; Sloot, W.N.; Rose, Ursula M.; Leeuw, R. de; Hanssen, Rob; Verheijden, Gijs

doi:10.1016/j.ejphar.2010.10.078

Cited by 33 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While initial studies employing gonadotrophins administered them via intramuscular injection, these medications are now routinely delivered safely and effectively via subcutaneous injection contribute to adherence. Moreover, the emergence of long-acting FSH preparations [66] now on the market may also hold promise for CHH men undergoing fertility induction.…”

Section: Approaches To Fertility Treatment Iii: Combined Gonadotrophimentioning

confidence: 97%

Gonadotrophin replacement for induction of fertility in hypogonadal men

Dwyer

Raivio

Pitteloud

2015

Best Practice & Research Clinical Endocrinology & Metab

102

View full text Add to dashboard Cite

Section: Approaches To Fertility Treatment Iii: Combined Gonadotrophimentioning

confidence: 97%

Gonadotrophin replacement for induction of fertility in hypogonadal men

Dwyer

Raivio

Pitteloud

2015

Best Practice & Research Clinical Endocrinology & Metab

102

View full text Add to dashboard Cite

“…Herein we also show that the late administration of CFα allows to add GnRH-antagonist from day 8 of the cycle instead than from day 5, as suggested when CFα is given on day 2 to expected normal responders (12,13); this is another issue that further lowers the number of injections. In the present study, the late-start CFα protocol enabled us to complete COS with an average total number of injections of 7.8±3.8 (range [4][5][6][7][8][9][10][11], which is definitely low in comparison with a standard COS, lower than observed after day 2 CFα administration (12,13), and significantly lower than observed in case of daily rFSH administration from day 4 of the cycle. This could possibly increase the patients' satisfaction and compliance to treatment and, on the other side, decrease the economical costs of IVF for medications.…”

Section: Discussionmentioning

confidence: 66%

“…CFα has the ideal kinetic to be applied in late-start protocols, when exogenous gonadotropin administration is started on day 4 of the menstrual cycle. Circulating FSH peak is reached approximately 24 h after CFα is injected subcutaneously, more quickly than after repeated rFSH daily injections, and sustained FSH levels are maintained for 7 days due to the long half-life of the molecule (7,10,11). In practical terms, when CFα is injected on day 4 of the cycle, blood FSH peak is reached on day 5 and steady FSH levels are maintained until day 11, when only some patients would need further FSH administration to complete follicular growth.…”

Section: Discussionmentioning

confidence: 99%

“…The carboxy-terminal peptide addition to FSH maintains the specific binding to FSH receptor and does not confer any LH activity to the molecule (5, 6), but changes its kinetic (7). After a single subcutaneous injection, CFα reaches peak serum levels after approximately 24 h, and having a long circulating half-life, provides a reliable FSH stimulus able to initiate and sustain multiple follicular development for 7 days (7)(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case–control study

Revelli

Pittatore

Casano

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Objective To investigate efficacy and safety of a controlled ovarian stimulation (COS) protocol in which a single dose of Corifollitropin-alfa (CFα) was administered on day 4 of a GnRH-antagonist cycle. Design Cohort case-control study. Setting University Hospital. Patients One hundred twenty-two normally cycling women expected to be normal responders to COS. Interventions In 61 patients, CFα (100-150 μg) was injected subcutaneously on day 4 of a spontaneous menstrual cycle; a GnRH-antagonist was added from day 8 (fixed protocol; 0.25 mg/day). If needed to complete follicular maturation, recombinant FSH (rFSH) daily injections (150/200 IU/day) were given from day 11. A control group of 61 matched women was stimulated with daily subcutaneous injections of rFSH (100-150 U/day) from day 4 of the cycle, and received GnRH-antagonist (0.25 mg/day) from day 8. IVF or ICSI was performed according to the sperm characteristics, and 1-2 embryos were transferred in utero under US guidance on day 2.Main outcome measures Number of retrieved cumulusoocyte complexes (COCs), clinical pregnancy rate (PR), implantation rate (IR), ongoing PR at 10 weeks, number of injections/cycle, ovarian hyperstimulation syndrome (OHSS) rate.Results No cycle was cancelled and the mean number of retrieved COCs was comparable in patients and controls. About 60 % of CF-alfa treated women had no need of daily rFSH addition, and the mean number of injections/cycle was significantly lower in the CF-alfa group than in controls (p<0.05). The ongoing PR/transfer was 36.8 % in CF-alfa group and 37.5 % in controls. No patient developed severe OHSS, and the incidence of moderate OHSS was similar in cases and controls. Conclusions CFα may be started on day 4 of the cycle obtaining results comparable to those of a COS using day 4-start daily rFSH, with significantly less injections and a similar risk of OHSS.

show abstract

“…Corifollitropin alfa is devoid of LH activity. As such, it interacts exclusively with FSH receptors and has a plasma half-life of 65 h [9,88]. The optimal corifollitropin dose has been calculated to be 100 mcg for women with a body weight ≤ 60 kg and 150 mcg for women with a body weight > 60 kg.…”

Section: Long-acting Fsh Preparationsmentioning

confidence: 99%